

Polyarticular Juvenile Idiopathic Arthritis Drugs Market - 2021

<https://marketpublishers.com/r/PF7FC075D89FEN.html>

Date: May 2025

Pages: 219

Price: US\$ 2,999.00 (Single User License)

ID: PF7FC075D89FEN

Abstracts

The Polyarticular Juvenile Idiopathic Arthritis Drugs Market was valued at USD 1,588.40 million in 2021 and is anticipated to reach by , at a CAGR of 0.066 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Polyarticular Juvenile Idiopathic Arthritis Drugs Market.

This report delivers a comprehensive overview of the Polyarticular Juvenile Idiopathic Arthritis Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Polyarticular Juvenile Idiopathic Arthritis Drugs Market. The Polyarticular Juvenile Idiopathic Arthritis Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2021–.

Polyarticular Juvenile Idiopathic Arthritis Drugs Market Scope:

By Drug Type

Disease-modifying antirheumatic drug

Nonsteroidal anti-inflammatory drugs

Biologics

Corticosteroids

Others

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Key Players

Pfizer Inc.

Biocon Ltd.

Coherus BioSciences Inc.

Livzon Pharmaceutical Group Inc.

Momenta Pharmaceuticals Inc.

Mycenax Biotech Inc.

Oncobiologics Inc.

Oncodesign SA

Panacea Biotec Ltd.

Regeneron Pharmaceuticals Inc.

Sandoz International GmbH

UCB SA List not Exhaustive

Major Highlights

This report delivers a comprehensive overview of the Polyarticular Juvenile Idiopathic Arthritis Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Polyarticular Juvenile Idiopathic Arthritis Drugs Market. The Polyarticular Juvenile Idiopathic Arthritis Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2021–.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the

latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. SCOPE AND METHODOLOGY

- 1.1. Research Methodology
- 1.2. Scope of the Market

2. KEY TRENDS AND DEVELOPMENTS

3. EXECUTIVE SUMMARY

- 3.1. Market Snippet by Drug Type
- 3.2. Market Snippet by Distribution Channel
- 3.3. Market Snippet by Region

4. MARKET DYNAMICS

- 4.1. Market impacting factors
 - 4.1.1. Drivers
 - 4.1.1.1. The prevalence of orthopedic cases will drive the market growth.
 - 4.1.1.2. Technological advancements in digital X-ray devices
 - 4.1.2. Restraints
 - 4.1.2.1. Risk of adverse effects from radiation exposure
 - 4.1.3. Opportunities
- 4.2. Impact analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's five forces analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Reimbursement Analysis

6. COVID-19 ANALYSIS

- 6.1. Analysis of Covid-19 on the Market
 - 6.1.1. Before COVID-19 Market Scenario
 - 6.1.2. Present COVID-19 Market Scenario

- 6.1.3. After COVID-19 or Future Scenario
- 6.2. Pricing Dynamics Amid Covid-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion

7. BY DRUG TYPE

- 7.1. Introduction
 - 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Drug Type Segment
 - 7.1.2. Market attractiveness index, By Drug Type Segment
- 7.2. Disease-modifying antirheumatic drug*
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis, US\$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
 - 7.2.3. Sulfasalazine
 - 7.2.4. Leflunomide
 - 7.2.5. Methotrexate
 - 7.2.6. Others
- 7.3. Nonsteroidal anti-inflammatory drugs
 - 7.3.1. Meloxicam
 - 7.3.2. Naproxen
 - 7.3.2.1. Aleve
 - 7.3.2.2. Naprelan
 - 7.3.2.3. Naprosyn
 - 7.3.3. Others
- 7.4. Biologics
 - 7.4.1. Abatacept
 - 7.4.2. Adalimumab
 - 7.4.3. Etanercept
 - 7.4.4. Infliximab
 - 7.4.5. Rituximab
 - 7.4.6. Tocilizumab
 - 7.4.7. Others
- 7.5. Corticosteroids
- 7.6. Others

8. BY DISTRIBUTION CHANNEL

8.1. Introduction

8.1.1. Market size analysis, and y-o-y growth analysis (%), By Distribution Channel Segment

8.1.2. Market attractiveness index, By Distribution Channel Segment

8.2. Hospital Pharmacies*

8.2.1. Introduction

8.2.2. Market Size Analysis, US\$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029

8.3. Retail Pharmacies

8.4. Online Pharmacies

8.5. Others

9. BY REGION

9.1. Introduction

9.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region

9.1.2. Market Attractiveness Index, By Region

9.2. North America

9.2.1. Introduction

9.2.2. Key region-specific dynamics

9.2.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug Type

9.2.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel

9.2.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country

9.2.5.1. U.S.

9.2.5.2. Canada

9.2.5.3. Mexico

9.3. South America

9.3.1. Introduction

9.3.2. Key Region-Specific Dynamics

9.3.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug Type

9.3.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel

9.3.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country

9.3.5.1. Brazil

9.3.5.2. Argentina

9.3.5.3. Rest of South America

9.4. Europe

9.4.1. Introduction

9.4.2. Key Region-Specific Dynamics

- 9.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug Type
- 9.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel
- 9.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
 - 9.4.5.1. Germany
 - 9.4.5.2. U.K.
 - 9.4.5.3. France
 - 9.4.5.4. Spain
 - 9.4.5.5. Italy
 - 9.4.5.6. Rest of Europe

9.5. Asia Pacific

- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug Type
- 9.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel
- 9.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
 - 9.5.5.1. China
 - 9.5.5.2. India
 - 9.5.5.3. Japan
 - 9.5.5.4. Australia
 - 9.5.5.5. Rest of Asia Pacific

9.6. Middle East and Africa

- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug Type
- 9.6.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel

10. COMPETITIVE LANDSCAPE

- 10.1. Competitive scenario
- 10.2. Competitor strategy analysis
- 10.3. Market positioning/share analysis
- 10.4. Mergers and acquisitions analysis

11. COMPANY PROFILES

- 11.1. Pfizer Inc.*
 - 11.1.1. Company Overview
 - 11.1.2. Product Portfolio and Description
 - 11.1.3. Key Highlights

- 11.1.4. Financial Overview
- 11.2. Biocon Ltd.
- 11.3. Coherus BioSciences Inc.
- 11.4. Livzon Pharmaceutical Group Inc.
- 11.5. Momenta Pharmaceuticals Inc.
- 11.6. Mycenax Biotech Inc.
- 11.7. Oncobiologics Inc.
- 11.8. Oncodesign SA
- 11.9. Panacea Biotec Ltd.
- 11.10. Regeneron Pharmaceuticals Inc.
- 11.11. Sandoz International GmbH
- 11.12. UCB SA List not Exhaustive*

12. DATAM INTELLIGENCE

- 12.1. Appendix
- 12.2. About us and services
- 12.3. Contact us

I would like to order

Product name: Polyarticular Juvenile Idiopathic Arthritis Drugs Market - 2021

Product link: <https://marketpublishers.com/r/PF7FC075D89FEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PF7FC075D89FEN.html>